A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117



Joanna H Tong, Sai F Yeung, Anthony W H Chan, Lau Y Chung, Shuk L Chau, Raymond Wai Ming Lung, Carol Y Tong, Chit Chow, Edith K Y Tin, Yau H Yu, Hui Li, Yi Pan, Wing P Chak, Calvin S H Ng, Tony S K Mok, Ka F To. Clin Cancer Res 2016
Times Cited: 199




List of shared articles



Times cited

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova,[...]. Clin Cancer Res 2021
19

Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
Takashi Seto, Kadoaki Ohashi, Shunichi Sugawara, Makoto Nishio, Masayuki Takeda, Keisuke Aoe, Sanae Moizumi, Satoshi Nomura, Takeshi Tajima, Toyoaki Hida. Cancer Sci 2021
2

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
2

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Matthew Lee, Prantesh Jain, Feng Wang, Patrick C Ma, Alain Borczuk, Balazs Halmos. Expert Opin Ther Targets 2021
0

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.
Caroline E McCoach, Aiming Yu, David R Gandara, Jonathan W Riess, Daniel P Vang, Tiahong Li, Primo N Lara, Matthew Gubens, Frances Lara, Philip C Mack,[...]. JCO Precis Oncol 2021
1


Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
Victor Moreno, Richard Greil, Jeffrey Yachnin, Margarita Majem, Martin Wermke, Hendrik-Tobias Arkenau, Jean-Rene Basque, Prasanna Kumar Nidamarthy, Shruti Kapoor, Xiaoming Cui,[...]. Clin Ther 2021
0



MET Amplification in Non-Small Cell Lung Cancer (NSCLC)-A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting.
Christoph Schubart, Robert Stöhr, Lars Tögel, Florian Fuchs, Horia Sirbu, Gerhard Seitz, Ruth Seggewiss-Bernhardt, Rumo Leistner, William Sterlacci, Michael Vieth,[...]. Cancers (Basel) 2021
0

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Carlo Genova, Giovanni Rossi, Marco Tagliamento, Erika Rijavec, Federica Biello, Luigi Cerbone, Lodovica Zullo, Francesco Grossi. Expert Rev Respir Med 2020
8

Progress on treatment of MET signaling pathway in non-small cell lung cancer.
Xiaoqing Yu, Sizhe Yu, Yun Fan. Int J Clin Oncol 2020
1


MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
27

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
19

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Yubo Wang, Panwen Tian, Lei Xia, Li Li, Rui Han, Mengxiao Zhu, Analyn Lizaso, Tian Qin, Min Li, Bing Yu,[...]. Lung Cancer 2020
5

Molecular therapeutic targets in non-small cell lung cancer.
Kamya Sankar, Shirish M Gadgeel, Angel Qin. Expert Rev Anticancer Ther 2020
8

Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd. Onco Targets Ther 2020
8

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Expert Opin Emerg Drugs 2020
3

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Ulrike Glaenzel, Yi Jin, Regine Hansen, Kirsten Schroer, Gholamreza Rahmanzadeh, Ulrike Pfaar, Jan Jaap van Lier, Hubert Borell, Axel Meissner, Gian Camenisch,[...]. Drug Metab Dispos 2020
2

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
114

The METeoric rise of MET in lung cancer.
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo. Cancer 2020
7

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study.
Xue-Wen Liu, Xin-Ru Chen, Yu-Ming Rong, Ning Lyu, Chun-Wei Xu, Fang Wang, Wen-Yong Sun, San-Gao Fang, Jing-Ping Yuan, Hui-Juan Wang,[...]. Transl Oncol 2020
3


Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
Jordi Remon, Myung-Ju Ahn, Nicolas Girard, Melissa Johnson, Dong-Wan Kim, Gilberto Lopes, Rathi N Pillai, Benjamin Solomon, Guillermo Villacampa, Qing Zhou. J Thorac Oncol 2019
40